Immunomet therapeutics
Developing Novel Cancer Drugs by Targeting Metabolism
- Website
- immunomet.com
- Last Round
- Series COct 2022
- Rounds
- 1
About
ImmunoMet Therapeutics develops lixumistat (IM156), a clinical-stage OxPhos inhibitor targeting cellular metabolism to treat cancer and fibrosis.
Summary
Immunomet therapeutics is a Biotech company based in United States. Its most recent funding was a Series C round in Oct 2022.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2022
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/immunomet-therapeutics"><img src="https://indexed.vc/api/badge/company/immunomet-therapeutics" alt="Immunomet therapeutics on Indexed.vc" width="260" height="76" /></a>